http://purl.org/np/RApbj7AFqp0b-yO7Jx72dSTD6lDBm1Sfq_0MJdkJlSsVw#Head
http://purl.org/np/RApbj7AFqp0b-yO7Jx72dSTD6lDBm1Sfq_0MJdkJlSsVw
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RApbj7AFqp0b-yO7Jx72dSTD6lDBm1Sfq_0MJdkJlSsVw#assertion
http://purl.org/np/RApbj7AFqp0b-yO7Jx72dSTD6lDBm1Sfq_0MJdkJlSsVw
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RApbj7AFqp0b-yO7Jx72dSTD6lDBm1Sfq_0MJdkJlSsVw#provenance
http://purl.org/np/RApbj7AFqp0b-yO7Jx72dSTD6lDBm1Sfq_0MJdkJlSsVw
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RApbj7AFqp0b-yO7Jx72dSTD6lDBm1Sfq_0MJdkJlSsVw#pubinfo
http://purl.org/np/RApbj7AFqp0b-yO7Jx72dSTD6lDBm1Sfq_0MJdkJlSsVw
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RApbj7AFqp0b-yO7Jx72dSTD6lDBm1Sfq_0MJdkJlSsVw#assertion
http://purl.obolibrary.org/obo/DOID_9538
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RApbj7AFqp0b-yO7Jx72dSTD6lDBm1Sfq_0MJdkJlSsVw#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_9538
http://purl.org/np/RApbj7AFqp0b-yO7Jx72dSTD6lDBm1Sfq_0MJdkJlSsVw#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RApbj7AFqp0b-yO7Jx72dSTD6lDBm1Sfq_0MJdkJlSsVw#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB09570
http://purl.org/np/RApbj7AFqp0b-yO7Jx72dSTD6lDBm1Sfq_0MJdkJlSsVw#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RApbj7AFqp0b-yO7Jx72dSTD6lDBm1Sfq_0MJdkJlSsVw#association
http://www.w3.org/2000/01/rdf-schema#label
ninlaro is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy ninlaro is a proteasome inhibitor indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy 1
http://purl.org/np/RApbj7AFqp0b-yO7Jx72dSTD6lDBm1Sfq_0MJdkJlSsVw#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RApbj7AFqp0b-yO7Jx72dSTD6lDBm1Sfq_0MJdkJlSsVw#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RApbj7AFqp0b-yO7Jx72dSTD6lDBm1Sfq_0MJdkJlSsVw#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB09570
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RApbj7AFqp0b-yO7Jx72dSTD6lDBm1Sfq_0MJdkJlSsVw#provenance
http://purl.org/np/RApbj7AFqp0b-yO7Jx72dSTD6lDBm1Sfq_0MJdkJlSsVw#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RApbj7AFqp0b-yO7Jx72dSTD6lDBm1Sfq_0MJdkJlSsVw#pubinfo
http://purl.org/np/RApbj7AFqp0b-yO7Jx72dSTD6lDBm1Sfq_0MJdkJlSsVw#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RApbj7AFqp0b-yO7Jx72dSTD6lDBm1Sfq_0MJdkJlSsVw#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RApbj7AFqp0b-yO7Jx72dSTD6lDBm1Sfq_0MJdkJlSsVw#sig
http://purl.org/nanopub/x/hasSignature
D/tdjG3PCvVvIEMKgghCIGs+eVHzBK1PNh6voLFxTVFQtdn49tYfKJ+TmNVxreHNiXfqCkNpeBzn5S2WQWZQ6Wvq7RBLXzbBGBitG0y1UDa1XrWGt3xtVcVeVP5cEj8jzWCH11qIr0W/JaI5RaB4Uia32s29avh8Yw6ewaOtlhU=
http://purl.org/np/RApbj7AFqp0b-yO7Jx72dSTD6lDBm1Sfq_0MJdkJlSsVw#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RApbj7AFqp0b-yO7Jx72dSTD6lDBm1Sfq_0MJdkJlSsVw
http://purl.org/np/RApbj7AFqp0b-yO7Jx72dSTD6lDBm1Sfq_0MJdkJlSsVw
http://purl.org/dc/terms/created
2021-06-12T12:40:01.858+02:00
http://purl.org/np/RApbj7AFqp0b-yO7Jx72dSTD6lDBm1Sfq_0MJdkJlSsVw
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RApbj7AFqp0b-yO7Jx72dSTD6lDBm1Sfq_0MJdkJlSsVw
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RApbj7AFqp0b-yO7Jx72dSTD6lDBm1Sfq_0MJdkJlSsVw
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RApbj7AFqp0b-yO7Jx72dSTD6lDBm1Sfq_0MJdkJlSsVw
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs